Mercer Global Advisors Inc. ADV Has $4.85 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Mercer Global Advisors Inc. ADV grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 8.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,666 shares of the company’s stock after purchasing an additional 949 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Medpace were worth $4,850,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Wealth Alliance grew its holdings in Medpace by 2.9% during the 2nd quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after acquiring an additional 27 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Medpace during the 2nd quarter worth about $5,383,000. Renaissance Technologies LLC grew its position in shares of Medpace by 38.3% in the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock valued at $182,692,000 after buying an additional 122,800 shares during the last quarter. Quantbot Technologies LP increased its stake in shares of Medpace by 189.9% in the second quarter. Quantbot Technologies LP now owns 6,712 shares of the company’s stock valued at $2,764,000 after buying an additional 4,397 shares during the period. Finally, Plato Investment Management Ltd raised its position in shares of Medpace by 84.6% during the second quarter. Plato Investment Management Ltd now owns 360 shares of the company’s stock worth $148,000 after acquiring an additional 165 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Shares of MEDP opened at $365.70 on Friday. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The company has a market cap of $11.33 billion, a PE ratio of 37.28, a P/E/G ratio of 1.74 and a beta of 1.35. The stock has a 50-day moving average of $378.15 and a 200-day moving average of $391.95.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same quarter in the previous year, the company posted $1.93 earnings per share. The company’s quarterly revenue was up 14.6% on a year-over-year basis. Analysts expect that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Analyst Ratings Changes

MEDP has been the subject of a number of recent analyst reports. Truist Financial initiated coverage on shares of Medpace in a research report on Thursday, August 1st. They set a “hold” rating and a $415.00 target price for the company. TD Cowen lowered their target price on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Robert W. Baird cut their price target on shares of Medpace from $430.00 to $413.00 and set an “outperform” rating on the stock in a research report on Friday. Deutsche Bank Aktiengesellschaft decreased their price target on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a report on Wednesday, July 24th. Finally, Mizuho began coverage on Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Moderate Buy” and an average price target of $420.88.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.